<DOC>
	<DOC>NCT02321306</DOC>
	<brief_summary>Open-label, multicenter study in adults with Primary Biliary Cirrhosis (PBC) designed to evaluate the long-term safety and tolerability of daily dosing with LUM001.</brief_summary>
	<brief_title>An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This is an open-label study in subjects with PBC who previously completed the LUM001 201 (CLARITY) study. The study is designed to investigate the long-term safety and tolerability of LUM001 treatment, with daily dosing for up to 2 years. Changes over time, compared to baseline, in liver enzymes, other biochemical markers associated with PBC, pruritus, and other quality of life measures will also be assessed.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<criteria>1. Completed a core treatment protocol of LUM001 in the treatment of Primary Biliary Cirrhosis. 2. Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures. 1. Presence of advanced liver disease. 2. History of nonadherence during the subject's participation in the core LUM001 treatment protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>